| Acute myeloid leukemia: a review A Pelcovits, R Niroula Rhode Island medical journal 103 (3), 38-40, 2020 | 358 | 2020 |
| Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia A Pelcovits, J Moore, B Bakow, R Niroula, P Egan, JL Reagan Supportive Care in Cancer 29, 5323-5327, 2021 | 20 | 2021 |
| Factor XIII Deficiency: A Review of Clinical Presentation and Management. A Pelcovits, F Schiffman, R Niroula Hematology/Oncology Clinics of North America 35 (6), 1171-1180, 2021 | 19 | 2021 |
| Impact of early palliative care on end-of-life outcomes in hematologic malignancies A Pelcovits, AJ Olszewski, D Decker, D Guyer, TW Leblanc, P Egan Journal of Palliative Medicine 25 (4), 556-561, 2022 | 11 | 2022 |
| Locoregional gastric cancer: a narrative review of multidisciplinary management A Pelcovits, K Almhanna Annals of Translational Medicine 8 (17), 2020 | 10 | 2020 |
| Advances in immunotherapy for the treatment of cutaneous T-cell lymphoma A Pelcovits, TA Ollila, AJ Olszewski Cancer Management and Research, 989-998, 2023 | 6 | 2023 |
| A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL). AJ Olszewski, SF Huntington, T Ollila, A Pelcovits, JB McMahon, ... Journal of Clinical Oncology 41 (16_suppl), TPS7588-TPS7588, 2023 | 5 | 2023 |
| Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study A Pelcovits, P Barth, JL Reagan, AJ Olszewski, V Rosati, R Wood, ... The Oncologist 28 (5), 462-e303, 2023 | 3 | 2023 |
| Risk factors for immune mediated adverse events with immune checkpoint inhibitors. A Pelcovits, H Mistry, R Chudasama, S Andrea, H Khurshid Journal of Clinical Oncology 39 (15_suppl), 2622-2622, 2021 | 3 | 2021 |
| Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR A Pelcovits, A Pandita, D Farmakiotis, P Egan Leukemia Research 100, 106473, 2021 | 3 | 2021 |
| Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects CJ Milrod, A Pelcovits, TA Ollila Frontiers in Oncology 14, 1397053, 2024 | 2 | 2024 |
| Progression‐free survival is a weakly predictive surrogate end‐point for overall survival in follicular lymphoma: A systematic review and meta‐analysis CJ Milrod, KW Kim, C Raker, TA Ollila, AJ Olszewski, A Pelcovits British Journal of Haematology, 2024 | 2 | 2024 |
| Risk Factors for Immunotherapy-related Adverse Events (IrAE) in Patients Treated With Immune Checkpoint Inhibitors MJ Hadfield, H Mistry, A Pelcovits, R Bansal, S Andrea, A Chergui, ... American Journal of Clinical Oncology 46 (4), 183-184, 2023 | 2 | 2023 |
| Enforcing the 4T: including a Hard Stop 4T calculator into the electronic medical record for heparin induced thrombocytopenia TA Ollila, A Zayac, AJ Olszewski, RW Hilliard, D Riley, A Pelcovits, ... Blood 132, 2442, 2018 | 2 | 2018 |
| Correlation between PFS and OS in FL: Implications for Clinical Trial Endpoint Selection C Milrod, KW Kim, T Ollila, AJ Olszewski, A Pelcovits Blood 142, 4395, 2023 | 1 | 2023 |
| Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL … J Sharp, P Strati, S Bhatta, JJ Huang, C Thomas, DK Reef, A Gorzewski, ... Blood 144, 2377, 2024 | | 2024 |
| Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis MJ Cortese, MM Herr, N Nair, J Romancik, N Grover, RS Bhansali, ... Blood 144, 525, 2024 | | 2024 |
| Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy BL Ellsworth, M Melody, N Epperla, N Grover, JT Romancik, MJ Cortese, ... Blood 144, 612, 2024 | | 2024 |
| Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma C Milrod, AD Chorzalska, J Morgan, MR Pardo, C Raker, T Ollila, SH Lee, ... Blood 144, 1614, 2024 | | 2024 |
| Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center … AJ Olszewski, M Matasar, SF Huntington, T Ollila, A Pelcovits, YK Tiger, ... Blood 144, 1644, 2024 | | 2024 |
Charles J. MilrodHematology/Oncology Fellow, Brown University在 brown.edu 的电子邮件经过验证
Charles J. MilrodHematology/Oncology Fellow, Brown University在 brown.edu 的电子邮件经过验证